Salt: Its Role in Chronic Kidney Disease

Journal of Renal Nutrition

Volumn 18, Issue 1, 2008, Pages 18-26

  Thijssen, Stephan ^a   Kitzler, Thomas M ^a   Levin, Nathan W ^a  

^a RENAL RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BLOOD PRESSURE; CHEMICALLY INDUCED DISORDER; CHRONIC KIDNEY FAILURE; DISEASE COURSE; DRUG EFFECT; HUMAN; HYPERTENSION; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PHYSIOLOGY; SODIUM INTAKE;

BLOOD PRESSURE; DISEASE PROGRESSION; HUMANS; HYPERTENSION; KIDNEY FAILURE, CHRONIC; OXIDATIVE STRESS; SODIUM, DIETARY;

EID: 37049010093     PISSN: 10512276     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.jrn.2007.10.006     Document Type: Article

References (122)

1. Kurlansky M. Salt: a world history (2002), Walker and Co., New York
2. Campese V.M., and Park J. The kidney and hypertension: over 70 years of research. J Nephrol 19 (2006) 691-698
3. Ritz E., Dikow R., Morath C., and Schwenger V. Salt-a potential "uremic toxin"?. Blood Purif 24 (2006) 63-66
4. Charra B. Fluid balance, dry weight, and blood pressure in dialysis. Hemodial Int 11 (2007) 21-31
5. Levin N.W., Zhu F., and Keen M. Interdialytic weight gain and dry weight. Blood Purif 19 (2001) 217-221
6. Chan C.T., Hanly P., Gabor J., Picton P., Pierratos A., and Floras J.S. Impact of nocturnal hemodialysis on the variability of heart rate and duration of hypoxemia during sleep. Kidney Int 65 (2004) 661-665
7. Cook N.R., Cutler J.A., Obarzanek E., et al. Long term effects of dietary sodium reduction on cardiovascular disease outcomes: observational follow-up of the Trials of Hypertension Prevention (TOHP). Br Med J [Clin Res] 334 (2007) 885
8. Pozzoni P., Di Filippo S., Pontoriero G., and Locatelli F. Effectiveness of sodium and conductivity kinetic models in predicting end-dialysis plasma water sodium concentration: preliminary results of a single-center experience. Hemodial Int 11 (2007) 169-177
9. Charra B., and Chazot C. The neglect of sodium restriction in dialysis patients. A short review. Hemodial Int 7 (2003) 342-347
10. Titze J., Bauer K., Schafflhuber M., et al. Internal sodium balance in DOCA-salt rats: a body composition study. Am J Physiol Renal Physiol 289 (2005) F793-F802
11. Titze J., Shakibaei M., Schafflhuber M., et al. Glycosaminoglycan polymerization may enable osmotically inactive Na+ storage in the skin. Am J Physiol Heart Circ Physiol 287 (2004) H203-H208
12. Carrino D.A., Onnerfjord P., Sandy J.D., et al. Age-related changes in the proteoglycans of human skin. Specific cleavage of decorin to yield a major catabolic fragment in adult skin. J Biol Chem 278 (2003) 17566-17572
13. Gerzer R., and Heer M. Regulation of body fluid and salt homeostasis-from observations in space to new concepts on earth. Curr Pharm Biotechnol 6 (2005) 299-304
14. Noakes T.D., Sharwood K., Speedy D., et al. Three independent biological mechanisms cause exercise-associated hyponatremia: evidence from 2,135 weighed competitive athletic performances. Proc Natl Acad Sci USA 102 (2005) 18550-18555
15. Benstein J.A., Feiner H.D., Parker M., and Dworkin L.D. Superiority of salt restriction over diuretics in reducing renal hypertrophy and injury in uninephrectomized SHR. Am J Physiol 258 (1990) F1675-F1681
16. Sanders M.W., Fazzi G.E., Janssen G.M., Blanco C.E., and De Mey J.G. High sodium intake increases blood pressure and alters renal function in intrauterine growth-retarded rats. Hypertension 46 (2005) 71-75
17. Sanders P.W. Salt intake, endothelial cell signaling, and progression of kidney disease. Hypertension 43 (2004) 142-146
18. Sanders P.W., Gibbs C.L., Akhi K.M., et al. Increased dietary salt accelerates chronic allograft nephropathy in rats. Kidney Int 59 (2001) 1149-1157
19. Suzuki H., Yamamoto T., Ikegaya N., and Hishida A. Dietary salt intake modulates progression of antithymocyte serum nephritis through alteration of glomerular angiotensin II receptor expression. Am J Physiol Renal Physiol 286 (2004) F267-F277
20. Yu H.C., Burrell L.M., Black M.J., et al. Salt induces myocardial and renal fibrosis in normotensive and hypertensive rats. Circulation 98 (1998) 2621-2628
21. du Cailar G., and Mimran A. Sodium and left ventricular hypertrophy in patients with hypertension. [in French]. Arch Mal Coeur 88 (1995) 15-19
22. du Cailar G., Mimran A., Fesler P., Ribstein J., Blacher J., and Safar M.E. Dietary sodium and pulse pressure in normotensive and essential hypertensive subjects. J Hypertens 22 (2004) 697-703
23. Messerli F.H., Schmieder R.E., and Weir M.R. Salt. A perpetrator of hypertensive target organ disease?. Arch Intern Med 157 (1997) 2449-2452
24. Cianciaruso B., Bellizzi V., Minutolo R., et al. Salt intake and renal outcome in patients with progressive renal disease. Miner Electrolyte Metab 24 (1998) 296-301
25. Himmelfarb J., and Hakim R.M. Oxidative stress in uremia. Curr Opin Nephrol Hypertens 12 (2003) 593-598
26. Himmelfarb J., Stenvinkel P., Ikizler T.A., and Hakim R.M. The elephant in uremia: oxidant stress as a unifying concept of cardiovascular disease in uremia. Kidney Int 62 (2002) 1524-1538
27. Ikizler T.A., Morrow J.D., Roberts L.J., et al. Plasma F2-isoprostane levels are elevated in chronic hemodialysis patients. Clin Nephrol 58 (2002) 190-197
28. Oberg B.P., McMenamin E., Lucas F.L., et al. Increased prevalence of oxidant stress and inflammation in patients with moderate to severe chronic kidney disease. Kidney Int 65 (2004) 1009-1016
29. Vaziri N.D. Roles of oxidative stress and antioxidant therapy in chronic kidney disease and hypertension. Curr Opin Nephrol Hypertens 13 (2004) 93-99
30. Buczynski A., Wachowicz B., Kedziora-Kornatowska K., Tkaczewski W., and Kedziora J. Changes in antioxidant enzymes activities, aggregability and malonyldialdehyde concentration in blood platelets from patients with coronary heart disease. Atherosclerosis 100 (1993) 223-228
31. Ceriello A., Giugliano D., Quatraro A., and Lefebvre P.J. Anti-oxidants show an anti-hypertensive effect in diabetic and hypertensive subjects. Clin Sci 81 (1991) 739-742
32. Galley H.F., Thornton J., Howdle P.D., Walker B.E., and Webster N.R. Combination oral antioxidant supplementation reduces blood pressure. Clin Sci 92 (1997) 361-365
33. Lacy F., O'Connor D.T., and Schmid-Schonbein G.W. Plasma hydrogen peroxide production in hypertensives and normotensive subjects at genetic risk of hypertension. J Hypertens 16 (1998) 291-303
34. Prabha P.S., Das U.N., Koratkar R., Sagar P.S., and Ramesh G. Free radical generation, lipid peroxidation and essential fatty acids in uncontrolled essential hypertension. Prostaglandins Leukot Essent Fatty Acids 41 (1990) 27-33
35. Romero J.C., and Reckelhoff J.F. State-of-the-art lecture. Role of angiotensin and oxidative stress in essential hypertension. Hypertension 34 (1999) 943-949
36. Russo C., Olivieri O., Girelli D., et al. Anti-oxidant status and lipid peroxidation in patients with essential hypertension. J Hypertens 16 (1998) 1267-1271
37. Wilcox C.S. Reactive oxygen species: roles in blood pressure and kidney function. Curr Hypertens Rep 4 (2002) 160-166
38. Makino A., Skelton M.M., Zou A.P., Roman R.J., and Cowley Jr. A.W. Increased renal medullary oxidative stress produces hypertension. Hypertension 39 (2002) 667-672
39. Roberts C.K., Vaziri N.D., Wang X.Q., and Barnard R.J. Enhanced NO inactivation and hypertension induced by a high-fat, refined-carbohydrate diet. Hypertension 36 (2000) 423-429
40. Vaziri N.D., Dicus M., Ho N.D., Boroujerdi-Rad L., and Sindhu R.K. Oxidative stress and dysregulation of superoxide dismutase and NADPH oxidase in renal insufficiency. Kidney Int 63 (2003) 179-185
41. Vaziri N.D., Liang K., and Ding Y. Increased nitric oxide inactivation by reactive oxygen species in lead-induced hypertension. Kidney Int 56 (1999) 1492-1498
42. Vaziri N.D., Ni Z., Oveisi F., and Trnavsky-Hobbs D.L. Effect of antioxidant therapy on blood pressure and NO synthase expression in hypertensive rats. Hypertension 36 (2000) 957-964
43. Cabassi A., Bouchard J.F., Dumont E.C., et al. Effect of antioxidant treatments on nitrate tolerance development in normotensive and hypertensive rats. J Hypertens 18 (2000) 187-196
44. Chen X., Touyz R.M., Park J.B., and Schiffrin E.L. Antioxidant effects of vitamins C and E are associated with altered activation of vascular NADPH oxidase and superoxide dismutase in stroke-prone SHR. Hypertension 38 (2001) 606-611
45. Duffy S.J., Gokce N., Holbrook M., et al. Treatment of hypertension with ascorbic acid. Lancet 354 (1999) 2048-2049
46. El Midaoui A., and de Champlain J. Prevention of hypertension, insulin resistance, and oxidative stress by alpha-lipoic acid. Hypertension 39 (2002) 303-307
47. Koo J.R., Ni Z., Oviesi F., and Vaziri N.D. Antioxidant therapy potentiates antihypertensive action of insulin in diabetic rats. Clin Exp Hypertens 24 (2002) 333-344
48. Koo J.R., and Vaziri N.D. Effects of diabetes, insulin and antioxidants on NO synthase abundance and NO interaction with reactive oxygen species. Kidney Int 63 (2003) 195-201
49. Noguchi T., Ikeda K., Sasaki Y., et al. Effects of vitamin E and sesamin on hypertension and cerebral thrombogenesis in stroke-prone spontaneously hypertensive rats. Hypertens Res 24 (2001) 735-742
50. Park J.B., Touyz R.M., Chen X., and Schiffrin E.L. Chronic treatment with a superoxide dismutase mimetic prevents vascular remodeling and progression of hypertension in salt-loaded stroke-prone spontaneously hypertensive rats. Am J Hypertens 15 (2002) 78-84
51. Schnackenberg C.G., Welch W.J., and Wilcox C.S. Normalization of blood pressure and renal vascular resistance in SHR with a membrane-permeable superoxide dismutase mimetic: role of nitric oxide. Hypertension 32 (1998) 59-64
52. Schnackenberg C.G., and Wilcox C.S. Two-week administration of Tempol attenuates both hypertension and renal excretion of 8-Iso prostaglandin f2alpha. Hypertension 33 (1999) 424-428
53. Vaziri N.D., Ding Y., and Ni Z. Compensatory up-regulation of nitric-oxide synthase isoforms in lead-induced hypertension: reversal by a superoxide dismutase-mimetic drug. J Pharmacol Exp Ther 298 (2001) 679-685
54. Vaziri N.D., Wang X.Q., Oveisi F., and Rad B. Induction of oxidative stress by glutathione depletion causes severe hypertension in normal rats. Hypertension 36 (2000) 142-146
55. Wu R., Lamontagne D., and de Champlain J. Antioxidative properties of acetylsalicylic acid on vascular tissues from normotensive and spontaneously hypertensive rats. Circulation 105 (2002) 387-392
56. Shah S.V., Baliga R., Rajapurkar M., and Fonseca V.A. Oxidants in chronic kidney disease. J Am Soc Nephrol 18 (2007) 16-28
57. Kitiyakara C., Chabrashvili T., Chen Y., et al. Salt intake, oxidative stress, and renal expression of NADPH oxidase and superoxide dismutase. J Am Soc Nephrol 14 (2003) 2775-2782
58. Lenda D.M., Sauls B.A., and Boegehold M.A. Reactive oxygen species may contribute to reduced endothelium-dependent dilation in rats fed high salt. Am J Physiol Heart Circ Physiol 279 (2000) H7-H14
59. Frisbee J.C., and Lombard J.H. Chronic elevations in salt intake and reduced renal mass hypertension compromise mechanisms of arteriolar dilation. Microvasc Res 56 (1998) 218-227
60. Frisbee J.C., and Lombard J.H. Acute elevations in salt intake and reduced renal mass hypertension compromise arteriolar dilation in rat cremaster muscle. Microvasc Res 57 (1999) 273-283
61. 2 and vasodilators during hypertension and elevated salt intake. Am J Physiol 273 (1997) H869-H877
62. Liu Y., Rusch N.J., and Lombard J.H. Loss of endothelium and receptor-mediated dilation in pial arterioles of rats fed a short-term high salt diet. Hypertension 33 (1999) 686-688
63. Boegehold M.A. Effect of dietary salt on arteriolar nitric oxide in striated muscle of normotensive rats. Am J Physiol 264 (1993) H1810-H1816
64. Boegehold M.A. Flow-dependent arteriolar dilation in normotensive rats fed low- or high-salt diets. Am J Physiol 269 (1995) H1407-H1414
65. Gryglewski R.J., Palmer R.M., and Moncada S. Superoxide anion is involved in the breakdown of endothelium-derived vascular relaxing factor. Nature 320 (1986) 454-456
66. Rubanyi G.M., and Vanhoutte P.M. Superoxide anions and hyperoxia inactivate endothelium-derived relaxing factor. Am J Physiol 250 (1986) H822-H827
67. Nurkiewicz T.R., and Boegehold M.A. High salt intake reduces endothelium-dependent dilation of mouse arterioles via superoxide anion generated from nitric oxide synthase. Am J Physiol Regul Integr Comp Physiol 292 (2007) R1550-R1556
68. Govers R., and Rabelink T.J. Cellular regulation of endothelial nitric oxide synthase. Am J Physiol Renal Physiol 280 (2001) F193-F206
69. Vasquez-Vivar J., Kalyanaraman B., Martasek P., et al. Superoxide generation by endothelial nitric oxide synthase: the influence of cofactors. Proc Natl Acad Sci USA 95 (1998) 9220-9225
70. Bagi Z., and Koller A. Lack of nitric oxide mediation of flow-dependent arteriolar dilation in type I diabetes is restored by sepiapterin. J Vasc Res 40 (2003) 47-57
71. Hong H.J., Hsiao G., Cheng T.H., and Yen M.H. Supplementation with tetrahydrobiopterin suppresses the development of hypertension in spontaneously hypertensive rats. Hypertension 38 (2001) 1044-1048
72. Jiang J., Valen G., Tokuno S., Thoren P., and Pernow J. Endothelial dysfunction in atherosclerotic mice: improved relaxation by combined supplementation with L-arginine-tetrahydrobiopterin and enhanced vasoconstriction by endothelin. Br J Pharmacol 131 (2000) 1255-1261
73. Zhu J., Mori T., Huang T., and Lombard J.H. Effect of high-salt diet on NO release and superoxide production in rat aorta. Am J Physiol Heart Circ Physiol 286 (2004) H575-H583
74. Rugale C., Delbosc S., Cristol J.P., Mimran A., and Jover B. Sodium restriction prevents cardiac hypertrophy and oxidative stress in angiotensin II hypertension. Am J Physiol Heart Circ Physiol 284 (2003) H1744-H1750
75. Ying W.Z., and Sanders P.W. Dietary salt modulates renal production of transforming growth factor-beta in rats. Am J Physiol 274 (1998) F635-F641
76. Ying W.Z., and Sanders P.W. Dietary salt increases endothelial nitric oxide synthase and TGF-beta1 in rat aortic endothelium. Am J Physiol 277 (1999) H1293-H1298
77. Akagi Y., Isaka Y., Arai M., et al. Inhibition of TGF-beta 1 expression by antisense oligonucleotides suppressed extracellular matrix accumulation in experimental glomerulonephritis. Kidney Int 50 (1996) 148-155
78. Border W.A., and Noble N.A. Cytokines in kidney disease: the role of transforming growth factor-beta. Am J Kidney Dis 22 (1993) 105-113
79. Border W.A., Noble N.A., Yamamoto T., et al. Natural inhibitor of transforming growth factor-beta protects against scarring in experimental kidney disease. Nature 360 (1992) 361-364
80. Border W.A., Okuda S., Languino L.R., Sporn M.B., and Ruoslahti E. Suppression of experimental glomerulonephritis by antiserum against transforming growth factor beta 1. Nature 346 (1990) 371-374
81. Border W.A., and Ruoslahti E. Transforming growth factor-beta in disease: the dark side of tissue repair. J Clin Invest 90 (1992) 1-7
82. Craven P.A., Studer R.K., Felder J., Phillips S., and DeRubertis F.R. Nitric oxide inhibition of transforming growth factor-beta and collagen synthesis in mesangial cells. Diabetes 46 (1997) 671-681
83. Dahly A.J., Hoagland K.M., Flasch A.K., Jha S., Ledbetter S.R., and Roman R.J. Antihypertensive effects of chronic anti-TGF-beta antibody therapy in Dahl S rats. Am J Physiol Regul Integr Comp Physiol 283 (2002) R757-R767
84. Herrera G.A., Shultz J.J., Soong S.J., and Sanders P.W. Growth factors in monoclonal light-chain-related renal diseases. Hum Pathol 25 (1994) 883-892
85. Isaka Y., Fujiwara Y., Ueda N., Kaneda Y., Kamada T., and Imai E. Glomerulosclerosis induced by in vivo transfection of transforming growth factor-beta or platelet-derived growth factor gene into the rat kidney. J Clin Invest 92 (1993) 2597-2601
86. Ishimura E., Morii H., Sterzel R.B., and Kashgarian M. Effect of transforming growth factor-beta on extracellular matrix production by cultured rat mesangial cells. Nippon Jinzo Gakkai Shi 35 (1993) 311-320
87. Kaname S., Uchida S., Ogata E., and Kurokawa K. Autocrine secretion of transforming growth factor-beta in cultured rat mesangial cells. Kidney Int 42 (1992) 1319-1327
88. Mozes M.M., Bottinger E.P., Jacot T.A., and Kopp J.B. Renal expression of fibrotic matrix proteins and of transforming growth factor-beta (TGF-beta) isoforms in TGF-beta transgenic mice. J Am Soc Nephrol 10 (1999) 271-280
89. Nakamura T., Miller D., Ruoslahti E., and Border W.A. Production of extracellular matrix by glomerular epithelial cells is regulated by transforming growth factor-beta 1. Kidney Int 41 (1992) 1213-1221
90. Shihab F.S., Andoh T.F., Tanner A.M., et al. Role of transforming growth factor-beta 1 in experimental chronic cyclosporine nephropathy. Kidney Int 49 (1996) 1141-1151
91. Shihab F.S., Tanner A.M., Shao Y., and Weffer M.I. Expression of TGF-beta 1 and matrix proteins is elevated in rats with chronic rejection. Kidney Int 50 (1996) 1904-1913
92. Shihab F.S., Yi H., Bennett W.M., and Andoh T.F. Effect of nitric oxide modulation on TGF-beta1 and matrix proteins in chronic cyclosporine nephrotoxicity. Kidney Int 58 (2000) 1174-1185
93. Tamaki K., Okuda S., Nakayama M., Yanagida T., and Fujishima M. Transforming growth factor-beta 1 in hypertensive renal injury in Dahl salt-sensitive rats. J Am Soc Nephrol 7 (1996) 2578-2589
94. Vieira Jr. J.M., Noronha I.L., Malheiros D.M., and Burdmann E.A. Cyclosporine-induced interstitial fibrosis and arteriolar TGF-beta expression with preserved renal blood flow. Transplantation 68 (1999) 1746-1753
95. Yamamoto T., Nakamura T., Noble N.A., Ruoslahti E., and Border W.A. Expression of transforming growth factor beta is elevated in human and experimental diabetic nephropathy. Proc Natl Acad Sci USA 90 (1993) 1814-1818
96. Yamamoto T., Noble N.A., Cohen A.H., et al. Expression of transforming growth factor-beta isoforms in human glomerular diseases. Kidney Int 49 (1996) 461-469
97. Yamamoto T., Noble N.A., Miller D.E., and Border W.A. Sustained expression of TGF-beta 1 underlies development of progressive kidney fibrosis. Kidney Int 45 (1994) 916-927
98. Zhu L., Herrera G.A., Murphy-Ullrich J.E., Huang Z.Q., and Sanders P.W. Pathogenesis of glomerulosclerosis in light chain deposition disease. Role for transforming growth factor-beta. Am J Pathol 147 (1995) 375-385
99. Ziyadeh F.N., Hoffman B.B., Han D.C., et al. Long-term prevention of renal insufficiency, excess matrix gene expression, and glomerular mesangial matrix expansion by treatment with monoclonal antitransforming growth factor-beta antibody in db/db diabetic mice. Proc Natl Acad Sci USA 97 (2000) 8015-8020
100. Ziyadeh F.N., Sharma K., Ericksen M., and Wolf G. Stimulation of collagen gene expression and protein synthesis in murine mesangial cells by high glucose is mediated by autocrine activation of transforming growth factor-beta. J Clin Invest 93 (1994) 536-542
101. Inoue N., Venema R.C., Sayegh H.S., Ohara Y., Murphy T.J., and Harrison D.G. Molecular regulation of the bovine endothelial cell nitric oxide synthase by transforming growth factor-beta 1. Arterioscler Thromb Vasc Biol 15 (1995) 1255-1261
102. Ying W.Z., and Sanders P.W. The interrelationship between TGF-beta1 and nitric oxide is altered in salt-sensitive hypertension. Am J Physiol Renal Physiol 285 (2003) F902-F908
103. Chen P.Y., St John P.L., Kirk K.A., Abrahamson D.R., and Sanders P.W. Hypertensive nephrosclerosis in the Dahl/Rapp rat. Initial sites of injury and effect of dietary L-arginine supplementation. Lab Invest 68 (1993) 174-184
104. Alderman M.H., Madhavan S., Cohen H., Sealey J.E., and Laragh J.H. Low urinary sodium is associated with greater risk of myocardial infarction among treated hypertensive men. Hypertension 25 (1995) 1144-1152
105. Alderman M.H., Cohen H., and Madhavan S. Dietary sodium intake and mortality: the National Health and Nutrition Examination Survey (NHANES I). Lancet 351 (1998) 781-785
106. Blythe W.B. Natural history of hypertension in renal parenchymal disease. Am J Kidney Dis 5 (1985) A50-A56
107. Coresh J., Wei G.L., McQuillan G., et al. Prevalence of high blood pressure and elevated serum creatinine level in the United States: findings from the Third National Health and Nutrition Examination Survey (1988-1994). Arch Intern Med 161 (2001) 1207-1216
108. Klag M.J., Whelton P.K., Randall B.L., et al. Blood pressure and end-stage renal disease in men. N Engl J Med 334 (1996) 13-18
109. Klahr S., Levey A.S., Beck G.J., et al. The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. Modification of Diet in Renal Disease Study Group. N Engl J Med 330 (1994) 877-884
110. Perry Jr. H.M., Miller J.P., Fornoff J.R., et al. Early predictors of 15-year end-stage renal disease in hypertensive patients. Hypertension 25 (1995) 587-594
111. Peterson J.C., Adler S., Burkart J.M., et al. Blood pressure control, proteinuria, and the progression of renal disease. The Modification of Diet in Renal Disease Study. Ann Intern Med 123 (1995) 754-762
112. Weir M.R. Diabetes and hypertension: blood pressure control and consequences. Am J Hypertens 12 Suppl (1999) 170S-178S
113. Weir M.R., and Dworkin L.D. Antihypertensive drugs, dietary salt, and renal protection: how low should you go and with which therapy?. Am J Kidney Dis 32 (1998) 1-22
114. Whelton P.K., and Klag M.J. Hypertension as a risk factor for renal disease. Review of clinical and epidemiological evidence. Hypertension 13 (1989) I19-I27
115. Campese V.M., Parise M., Karubian F., and Bigazzi R. Abnormal renal hemodynamics in black salt-sensitive patients with hypertension. Hypertension 18 (1991) 805-812
116. Bakris G.L., and Weir M.R. Salt intake and reductions in arterial pressure and proteinuria. Is there a direct link?. Am J Hypertens 9 Suppl (1996) 200S-206S
117. Bigazzi R., Bianchi S., Baldari D., Sgherri G., Baldari G., and Campese V.M. Microalbuminuria in salt-sensitive patients. A marker for renal and cardiovascular risk factors. Hypertension 23 (1994) 195-199
118. Brenner B.M. Hemodynamically mediated glomerular injury and the progressive nature of kidney disease. Kidney Int 23 (1983) 647-655
119. Zatz R., Dunn B.R., Meyer T.W., Anderson S., Rennke H.G., and Brenner B.M. Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension. J Clin Invest 77 (1986) 1925-1930
120. Heeg J.E., de Jong P.E., van der Hem G.K., and de Zeeuw D. Efficacy and variability of the antiproteinuric effect of ACE inhibition by lisinopril. Kidney Int 36 (1986) 272-279
121. Bakris G.L., and Smith A. Effects of sodium intake on albumin excretion in patients with diabetic nephropathy treated with long-acting calcium antagonists. Ann Intern Med 125 (1996) 201-204
122. Weir M.R., Chrysant S.G., McCarron D.A., et al. Influence of race and dietary salt on the antihypertensive efficacy of an angiotensin-converting enzyme inhibitor or a calcium channel antagonist in salt-sensitive hypertensives. Hypertension 31 (1998) 1088-1096